|Bid||3.50 x 1000|
|Ask||5.35 x 100|
|Day's Range||3.91 - 4.10|
|52 Week Range||3.20 - 7.49|
|PE Ratio (TTM)||-3.14|
|Earnings Date||Jul 26, 2017 - Jul 31, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||7.95|
Study conducted in individuals who had previously received current standard of care LONDON , June 21, 2017 /PRNewswire/ -- GSK (LSE/NYSE: GSK) today will be presenting new results from a clinical study ...
LEXINGTON, Mass., June 21, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced that GlaxoSmithKline's shingles vaccine candidate, Shingrix, containing Agenus' proprietary immune adjuvant, QS-21 Stimulon®, triggered a strong immune response in elderly patients previously treated with the current vaccine, Zostavax®, for the prevention of shingles.
LEXINGTON, Mass., June 21, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, June 28, 2017. The meeting will be held at the Company's headquarters located at 3 Forbes Road, Lexington, MA 02421. A live webcast will be accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts.